The much hyped Supreme Court ruling in June 2013, which declared that isolated human genes are not patentable, has significantly challenged Myriad Genetics' (MYGN) patent landscape. The stock has seen ~50% correction following the incident. However, I believe that the company's recent move to market Sividon Diagnostics' breast cancer test EndoPredict in Europe is a positive development. This, coupled with the company's plans to transform the entire hereditary cancer market towards myRisk platform through fiscal 2015, is expected to drive the stock higher again over the medium-term.
What Went Wrong?
MYGN offers the following molecular diagnostic tests:
- BRACAnalysis: For hereditary breast and ovarian cancer
- COLARIS / COLARIS AP: For hereditary colon cancer
Only subscribers can access this article, which is part of the PRO research library covering 3,619 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: